Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Downstaging radiotherapy and surgical transformation for initially unresectable or borderline resectable hepatocellular carcinoma: A phase II study.
Authors
Ting-Shi Su
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China
Ting-Shi Su , Wen-Feng Gong , Chang Zhao , Shi-Xiong Liang , Le-Qun Li , Bang-De Xiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiCTR1800015350
DOI
10.1200/JCO.2022.40.4_suppl.442
Abstract #
442
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Downstaging locally advanced hepatocellular carcinoma with selective internal radiation therapy.
First Author: Marjorie Hoang
Poster
2016 Gastrointestinal Cancers Symposium
A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).
First Author: Theodore S. Hong
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.
First Author: Changhoon Yoo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
First Author: Guoliang Shao